Thierry Chauche Biography and Net Worth

Thierry Chauche joined Sagimet as chief financial officer in May 2024, bringing over 20 years of financial and operational leadership experience in finance and healthcare companies. Most recently, he served as the chief financial officer of Provention Bio, a publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including Type 1 Diabetes, where he focused on the successful execution of several financings, the commercial launch of Tzield®, and the company acquisition by Sanofi in April 2023. Before Provention Bio, Mr. Chauche was the Vice President and Head of Strategic Financial Planning & Analysis at Alexion Pharmaceuticals. Prior to Alexion Pharmaceuticals, he served in roles of increasing responsibility at Intercept Pharmaceuticals, Novartis, and Rothschild & Cie. Mr. Chauche holds an MS in engineering from Ecole Des Ponts ParisTech and an MBA from the Wharton School of the University of Pennsylvania.

What is Thierry Chauche's net worth?: The estimated net worth of Thierry Chauche is at least $120.95 thousand as of February 10th, 2026. Mr. Chauche owns 15,688 shares of Sagimet Biosciences stock worth more than $120,954 as of July 15th. This net worth evaluation does not reflect any other investments that Mr. Chauche may own. Learn More about Thierry Chauche's net worth.
How do I contact Thierry Chauche?: The corporate mailing address for Mr. Chauche and other Sagimet Biosciences executives is , , . Sagimet Biosciences can also be reached via phone at 650-561-8600 and via email at [email protected]. Learn More on Thierry Chauche's contact information.
Has Thierry Chauche been buying or selling shares of Sagimet Biosciences?: Thierry Chauche has not been actively trading shares of Sagimet Biosciences within the last three months. Most recently, Thierry Chauche sold 1,312 shares of the business's stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a transaction totalling $7,032.32. Following the completion of the sale, the chief financial officer now directly owns 15,688 shares of the company's stock, valued at $84,087.68. Learn More on Thierry Chauche's trading history.
Who are Sagimet Biosciences' active insiders?: Sagimet Biosciences' insider roster includes Thierry Chauche (CFO), David Happel (Chief Executive Officer & Director), George Kemble (Chairman), Eduardo Martins (Chief Medical Officer), Elizabeth Rozek (General Counsel), and Beth Seidenberg (Director). Learn More on Sagimet Biosciences' active insiders.
Are insiders buying or selling shares of Sagimet Biosciences?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 135,636 shares worth more than $1,133,518.95. The most recent insider tranaction occured on February, 10th when CEO David Happel sold 12,101 shares worth more than $64,861.36. Insiders at Sagimet Biosciences own 14.7% of the company. Learn More about insider trades at Sagimet Biosciences.
Information on this page was last updated on 2/10/2026.

Thierry Chauche Insider Trading History at Sagimet Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/10/2026	Sell	1,312	$5.36	$7,032.32	15,688

Thierry Chauche Buying and Selling Activity at Sagimet Biosciences

Sagimet Biosciences Company Overview

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $7.88

$7.61

$7.90

50 Day Range

MA: $7.13

$6.30

$8.38

2 Week Range

Now: $7.88

$4.50

$11.41

Volume

787,739 shs

Average Volume

1,169,000 shs

Market Capitalization

$256.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.35